Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2003 Mar;43(3):226-32.

Costs of prostate cancer, metastatic to the bone, in the Netherlands.

Author information

  • 1Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3-105, 3000 DR Rotterdam, The Netherlands. groot@bmg.eur.nl

Abstract

OBJECTIVE:

To quantify medical costs associated with bone metastases in patients with prostate cancer. Bone metastases in patients with prostate cancer are associated with considerable morbidity, negatively impact quality of life, and can add substantially to medical costs, given a median survival of 30-35 months from diagnosis of bone metastases.

METHODS:

A retrospective cost analysis from both a community and university hospital in The Netherlands was conducted. Twenty-eight patient records (14 from each hospital) were investigated to assess the impact of skeletal-related events (SREs), including fractures, spinal cord compression, and radiotherapy, on total direct medical costs and cost of hospitalization. Costs are given in EUROS (Euros).

RESULTS:

The average total cost of treatment was Euros 13,051 per patient over the 24-month follow-up period, which includes an average cost of Euros 6973 per patient to treat SREs. Treatment of SREs more than doubled total treatment costs. Patients in this analysis experienced, on average, one SRE per year, and the cost of SREs varied from Euros 1187 to Euros 40,948.

CONCLUSIONS:

Occurrence of SREs contributes significantly to the cost of care for patients with advanced prostate cancer. These data suggest that bisphosphonates, which can reduce pain and SREs, may reduce healthcare costs.

Copyright 2003 Elsevier Science B.V.

PMID:
12600424
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk